Form 4: Indivior Director Keith Humphreys Granted RSUs

Indivior Pharmaceuticals, Inc. Director Keith Humphreys received a grant of 3,722 Restricted Stock Units, increasing his beneficial ownership.

Summary

• Director Keith Humphreys of Indivior Pharmaceuticals, Inc. was granted 3,722 Restricted Stock Units (RSUs) on January 26, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date.
• Vesting is contingent upon Mr. Humphreys' continued service to the Issuer on the vesting date.
• Following this transaction, Mr. Humphreys beneficially owns 9,524 shares of common stock directly.

Sentiment

Score: 7

Explanation: The RSU grant is a positive, routine event for director compensation, aligning interests with shareholders. It's not a major operational announcement but reflects standard governance.

Positives

• The grant of Restricted Stock Units aligns the director's interests with long-term shareholder value.
• The vesting schedule, tied to continued service, incentivizes retention of key leadership.

Future Outlook

The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to continued service. This indicates a future vesting event.

Industry Context

RSU grants are a common form of equity compensation for directors and executives across various industries, including pharmaceuticals, to align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice in corporate compensation structures, comparable to practices at companies like Pfizer, Johnson & Johnson, or Merck, which frequently use equity awards to incentivize leadership.
• The vesting schedule, tied to continued service, is typical for such awards, ensuring retention and alignment with long-term strategic goals, similar to how many S&P 500 companies structure their executive and director compensation plans.

Corporate Governance

Related Party Transactions

• The RSU grant is a transaction between the company and its director, which is a standard compensation event for a related party.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with long-term shareholder value, potentially leading to better governance and performance.
• Management: Reinforces the compensation structure for directors.

Next Steps

• The RSUs will vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine RSU grant to a director, which is a standard compensation practice and does not provide new information that would fundamentally alter the investment thesis for Indivior Pharmaceuticals. It reflects ongoing corporate governance and compensation alignment but is not a catalyst for a "buy" or "sell" decision. Therefore, a "hold" recommendation is appropriate as it confirms business as usual in terms of director incentives.

Keywords

Indivior Pharmaceuticals, INDV, Keith Humphreys, Restricted Stock Units, RSU grant, Director compensation, Insider transaction, Beneficial ownership